Nasdaq:SCYX
SCYNEXIS INC
A clinical-stage biopharma firm specializing in novel small molecule therapies for multidrug-resistant bacterial infections and other serious illnesses.
Key Metrics
Investment Thesis
Bull Case
Investors might consider SCYNEXIS for its differentiated technology platform targeting unmet medical needs in multidrug-resistant infections, which offers a potential path to significant market capture if clinical success is achieved. The company holds substantial liquid assets including $43.2M in marketable securities and $16.1M in cash equivalents, providing a runway to continue development activities without immediate dilution.
Bear Case
The stock carries high risk given the massive retained earnings deficit of $376.5M and negative operating cash flow, suggesting the business model may struggle to achieve self-sufficiency without continuous capital raises. The severe revenue drop from 2023 to 2024 combined with low gross profit margins indicates potential commercial weakness that could erode investor confidence and limit growth prospects.
About SCYNEXIS INC
SCYNEXIS Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapeutics to treat serious infectious diseases. The company primarily targets patients with multidrug-resistant bacterial infections and other severe conditions through its proprietary drug candidates in the United States, Europe, and Japan.
Analysis
Management Discussion
SCYNEXIS reported a net loss of $21.3M for the latest period, with operating profit turning negative at -$37.1M as general and administrative expenses rose to $14.5M against minimal cost of revenue. While the company maintained a healthy cash position with ending cash of $16.6M and marketable securities of $43.2M, the drastic year-over-year revenue contraction from 2023 suggests challenges in sustaining commercial momentum or managing pipeline transitions.
Industry Overview
The biopharmaceutical industry is currently grappling with a global antibiotic resistance crisis, creating urgent demand for innovative small molecule therapies that can penetrate bacterial defenses. Competitors in this space are racing to bring new assets to market, but success often depends on securing robust intellectual property rights and navigating complex regulatory pathways.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $5.1M | $140.1M | $3.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $5.1M | $140.1M | $3.7M |
| Operating Expenses | $90.8M | $67.5M | $40.9M |
| Operating Income | $-85.8M | $72.7M | $-37.1M |
| R&D | $27.3M | $30.9M | $26.4M |
| G&A | $63.0M | $20.9M | $14.5M |
| Stock-Based Comp | $3.7M | $2.6M | $3.3M |
| D&A | $606.0K | $580.0K | $0 |
| Amortization | $700.0K | $400.0K | — |
| Other OpEx | $628.0K | $15.6M | $0 |
| Non-Operating Income | $18.2M | $-5.5M | $16.0M |
| Interest Expense | $5.2M | $3.1M | — |
| Interest Income | $1.4M | $4.0M | $4.3M |
| Pre-Tax Income | $-67.5M | $67.2M | $-21.1M |
| Income Tax | $-4.7M | $138.0K | $151.0K |
| Continuing Ops | $-62.8M | $67.0M | $-21.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-62.8M | $67.0M | $-21.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-62.8M | $67.0M | $-21.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $79.1M | $102.1M | $72.2M |
| Cash & Equivalents | $45.8M | $34.0M | $16.1M |
| Marketable Securities | $27.7M | $40.3M | $43.2M |
| Accounts Receivable | $2.1M | $0 | — |
| Inventory | $899.0K | $0 | — |
| Prepaid Expenses | $2.5M | $5.5M | $2.2M |
| Other Current Assets | $55.0K | $22.2M | $10.7M |
| Long-Term Assets | $8.7M | $26.3M | $18.5M |
| Intangibles | $408.0K | $0 | — |
| Operating Leases | $2.6M | $2.4M | $2.1M |
| Other LT Assets | $5.7M | $23.9M | $16.4M |
| Total Assets | $87.8M | $128.4M | $90.6M |
| Current Liabilities | $17.6M | $16.3M | $24.1M |
| Accounts Payable | $5.9M | $7.1M | $4.6M |
| Current Leases | $282.0K | $340.0K | $407.0K |
| Other Current Liab | $5.8M | $1.3M | $15.3M |
| Long-Term Liabilities | $67.0M | $39.1M | $11.5M |
| LT Operating Leases | $2.9M | $2.6M | $2.2M |
| Other LT Liab | $64.0M | $36.6M | $9.3M |
| Total Liabilities | $84.6M | $55.5M | $35.6M |
| Shareholders' Equity | $3.2M | $73.0M | $55.1M |
| Paid-In Capital | $425.5M | $428.2M | $431.6M |
| Retained Earnings | $-422.3M | $-355.2M | $-376.5M |
| Total L&E | $87.8M | $128.4M | $90.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-62.8M | $67.0M | $-21.3M |
| Non-Cash Adjustments | $-12.6M | $-11.0M | $9.8M |
| Working Capital Changes | $-4.5M | $4.1M | $-12.5M |
| Cash from Operations | $-79.9M | $60.2M | $-24.0M |
| Cash from Investing | $-27.4M | $-34.9M | $6.2M |
| Cash from Financing | $48.6M | $-36.7M | $-139.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-58.7M | $-11.4M | $-18.0M |
| Beginning Cash | $104.7M | $46.0M | $34.6M |
| Ending Cash | $46.0M | $34.6M | $16.6M |
Frequently Asked Questions
How does SCYNEXIS INC make money?
The company's revenue is currently derived from commercial sales of its approved product, Scynexis (formerly known as the first FDA-approved drug utilizing a specific mechanism), alongside licensing fees and milestones associated with its pipeline candidates. Financial data indicates significant operating expenses driven by research and development activities totaling $26.4M, general and administrative costs of $14.5M, and share-based compensation of $3.3M.
What are the main risks for SCYX?
The company faces substantial financial risk due to negative operating cash flow of $24.0M and a retained earnings deficit of $376.5M, raising concerns about liquidity and the need for future financing. High reliance on non-operating income such as interest income of $4.3M suggests vulnerability to changing market rates or investment performance rather than core business profitability. The recent sharp decline in revenue from $140.1M in 2023 to $3.7M in 2024 indicates potential commercial instability or product lifecycle issues that could impact future funding capabilities.
What is SCYX's competitive advantage?
SCYNEXIS possesses a unique intellectual property portfolio centered on small molecule technology capable of penetrating bacterial biofilms, addressing the critical global need for treatments against multidrug-resistant organisms. The company benefits from a streamlined development platform that reduces time-to-market and cost compared to traditional large biologic molecules, offering a distinct value proposition in the infectious disease space.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.